Dear MRI Insider,
Researchers from Lille, France, have confirmed the promise of dynamic contrast-enhanced MRI for predicting the response of brain metastases in lung cancer patients.
Significantly, they think the technique can help enable clinicians to identify patients with a high risk of progression, individualize patient's oncological follow-up, and anticipate second-line treatments. To get the full details, click here.
When it comes to breast MRI, everybody pays attention when Dr. Christiane Kuhl speaks out. Last week, her group at Aachen University in Germany published the findings of a new study. Click here to read more.
The much-delayed investigation by the European Medicines Agency into gadolinium-based MR contrast agents has created massive uncertainty over the last year. Partly due to this regulatory haze, it looks like manganese-based products may replace gadolinium agents, at least for selected indications, writes Dr. Peter Rinck, PhD, in his latest column. To learn more, click here.
A leading figure in the development of MRI, Sir Peter Mansfield, PhD, died earlier this month. He shared the 2003 Nobel Prize in physiology or medicine with Paul Lauterbur, PhD. Click here to find out more. And to remind yourself how the long-running dispute over the prize resurfaced at ECR 2014, click here.
More standardized MRI acquisition protocols, along with better quantitative reporting tools, provide a greater understanding of the natural history of multiple sclerosis and allow accurate treatment monitoring of patients. That's the view of Dr. Paul Parizel, PhD, who will preside over ECR 2017 this week in Vienna. Click here for the story.
This letter features only a few of the many articles posted over the past few weeks in the MRI Community. Please scroll through the rest of our coverage below this message.
